The thesis
PanicFade v4 is a contrarian mean-reversion strategy built on a simple, literature-backed premise: markets overreact to negative headlines, and price reverts toward fundamentals once the panic exhausts. It buys large caps hit by sentiment below −0.4 that are already oversold (RSI14 under 35 and below their SMA20), and it sizes into the fear rather than waiting for confirmation. Exits are equally mechanical — RSI14 above 50 or a reclaim of the SMA20 books the reversion, while fresh lows on continued negativity trip a hard stop, the design's admission that some shocks are real fundamental breaks rather than noise.
The universe is deliberately conservative: 24 mega- and large-cap names spanning tech, financials, healthcare, staples, and energy. That matters — the reversion premium is far more reliable in liquid, well-covered names than in the small caps where sentiment shocks can be genuinely terminal.
Validation: the strong case
This is where PanicFade v4 earns attention. The walk-forward test ran four folds from September 2021 through August 2026, and all four were positive — 1.6%, 3.88%, 10.14%, and 21.7% respectively. Robustness statistics back that up: a Probabilistic Sharpe Ratio of 0.985 and a Deflated Sharpe of 0.56 across 27 trials, meaning the edge survives an honest haircut for multiple-testing luck. Most telling is the trajectory: the out-of-sample fold (May 2025–Aug 2026) posted a 21.7% return at a 2.44 Sharpe with only a 2.6% max drawdown. The strategy has been getting better on unseen data, not decaying — the opposite of the usual overfit signature.
The risks
Balance is warranted. The full-sample Sharpe is a modest 0.96 and CAGR just 6.79% — the headline 37.93% total return is spread across roughly five years, not a blistering run. Turnover is extreme at 5,807%, so the edge is real but thin per trade and sensitive to slippage and fees the backtest may understate. A pure long-contrarian book also carries directional risk: it has no answer to a regime where oversold keeps getting more oversold beyond its stops.
Live activity: silence
The most honest observation is that the live book is doing nothing. The last six scheduled runs — August 7 through 14 — each report 0 executed, 0 rejected, cash and total equity pinned at $10,000. No entry conditions have been met. That is arguably the strategy working as designed: it is patient by construction and simply refuses to trade a calm, un-panicked market. But a week of flat readings offers no live confirmation of the backtest, and prospective users should treat the paper record as the evidence base until a real panic gives PanicFade v4 something to fade.
Verdict
A rigorously validated, well-scoped mean-reversion strategy with a rare clean-sweep fold record — currently waiting, correctly, for the volatility it was built to exploit.